616.OnoratiF,MariscalcoG,RubinoAS,SerrainoF,SantiniF,MusazziA, KlersyC,SalaA,RenzulliA. Impactoflesionsetsonmid-termresults ofsurgicalablationprocedureforatrialfibrillation.JAmCollCardiol 2011;57:931–940.
617.Hugh Calkins, M.D., Stephan Willems, M.D., Edward P. Gerstenfeld, M.D.,AtulVerma,M.D.,RichardSchilling,M.D.,StefanH. Hohnloser, M.D.,KenOkumura,M.D.,Ph.D.,HarveySerota,M.D.,MatiasNordaby, M.D.,KellyGuiver,M. Sc.,BranislavBiss,M.D.,MarcA. Brouwer,M.D., Ph.D.,andMassimoGrimaldi,M.D.,Ph. D. UninterruptedDabigatran versus Warfarin for Ablation in Atrial Fibrillation (RE-CIRCUIT ClinicalTrials).NewEnglandJournalofMedicine,2017,DOI:10.1056/ NEJMoa1701005.
618.C. MichaelGibson,M.D.,RoxanaMehran,M.D.,ChristophBode,M.D., JonathanHalperin,M.D.,FreekW. Verheugt,M.D.,PeterWildgoose, Ph.D.,MaryBirmingham,Pharm.D.,JulianaIanus,Ph.D.,PaulBurton, M.D.,Ph.D.,MartinvanEickels,M.D.,SergeKorjian,M.D.,YazanDaaboul, M.D.,Gregory Y. H. Lip,M.D.,MarcCohen,M.D.,SteenHusted,M.D.,Eric D. Peterson,M.D.,M.P.H.,andKeithA. Fox,M.B.,Ch. B. Preventionof BleedinginPatientswithAtrialFibrillationUndergoingPCITheNew EnglandJournalofMedicine,2017,DOI:10.1056/NEJMoa1611594.
